×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Contact Us
About Us
Subscribe
My Portfolio
My Account
Contact Us
About Us
Subscribe
My Account
My Portfolio

Insider Transactions by Clague Laura

Symbol CompanyOwnerRelationshipDateTransactionCost# SharesValue ($)Total SharesFiling
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerMay 10, 2022Sale$21.5182517,74637,030May 12, 2022, 08:45 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerMay 11, 2022Sale$21.511,37529,57635,655May 12, 2022, 08:45 PM
GNSSGenasys Inc.Clague LauraDirectorApr 27, 2022Option Exercise$1.3350,00066,500284,311Apr 27, 2022, 07:02 PM
GNSSGenasys Inc.Clague LauraDirectorFeb 23, 2022Option Exercise$2.5633,71686,268218,027Feb 24, 2022, 01:54 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerJan 31, 2022Sale$27.401,23833,92137,855Feb 02, 2022, 04:17 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerJan 24, 2022Sale$24.982,06351,53429,253Jan 26, 2022, 04:34 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerJan 11, 2022Sale$27.407,500205,50031,316Jan 12, 2022, 04:05 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerAug 17, 2021Sale$17.121,40724,08531,316Aug 17, 2021, 07:34 PM
GNSSGenasys Inc.Clague LauraDirectorMar 10, 2021Option Exercise$3.1825,45680,865175,600Mar 12, 2021, 12:43 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerFeb 05, 2021Sale$31.412,25070,67234,473Feb 09, 2021, 04:29 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerFeb 08, 2021Sale$31.582,25071,05532,223Feb 09, 2021, 04:29 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerFeb 03, 2021Sale$28.913,625104,79933,348Feb 03, 2021, 09:30 PM
TVTXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerFeb 02, 2021Sale$30.753,625111,46936,973Feb 02, 2021, 09:19 PM
RTRXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerNov 24, 2020Sale$23.863,75089,47523,223Nov 25, 2020, 07:00 PM
RTRXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerNov 25, 2020Sale$22.723,75085,20019,473Nov 25, 2020, 07:00 PM
RTRXTravere Therapeutics, Inc.Clague LauraChief Financial OfficerNov 16, 2020Sale$23.987,500179,81319,473Nov 17, 2020, 09:00 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerNov 13, 2020Sale$23.617,500177,07126,973Nov 13, 2020, 09:24 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerSep 23, 2020Sale$18.481,50027,72019,473Sep 23, 2020, 08:00 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerSep 22, 2020Sale$18.591,50027,88520,973Sep 22, 2020, 09:18 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerMay 11, 2020Sale$14.951,25018,68721,250May 13, 2020, 09:00 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerMay 12, 2020Sale$17.111,77730,40120,000May 13, 2020, 09:00 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerMar 10, 2020Sale$15.024,00060,08022,500Mar 12, 2020, 07:43 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerMay 15, 2019Sale$17.781,25022,22514,750May 16, 2019, 09:37 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerMay 16, 2019Sale$18.711,25023,38713,500May 16, 2019, 09:37 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerFeb 11, 2019Sale$21.381,01721,74311,016Feb 13, 2019, 08:49 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerFeb 12, 2019Sale$21.501,01621,84410,000Feb 13, 2019, 08:49 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerDec 21, 2018Sale$21.833,75081,86012,933Dec 21, 2018, 08:19 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerDec 20, 2018Sale$22.083,75082,80415,783Dec 21, 2018, 08:19 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerNov 14, 2018Sale$23.733,75088,97016,183Nov 16, 2018, 07:16 PM
RTRXRetrophin, Inc.Clague LauraChief Financial OfficerNov 15, 2018Sale$24.313,75091,16712,824Nov 16, 2018, 07:16 PM
LRADLRAD CorpClague LauraDirectorSep 04, 2013Sale$0.7339,40028,87632,000Sep 06, 2013, 04:45 PM

Looking for more premium content?

We have created a comprehensive group of tools that allows you to estimate the intrinsic value of investments.

Subscribe